All lobbying filings
Manatt, Phelps, and Phillips
Manatt, Phelps, and Phillips filed a Q1 amendment for Denali Therapeutics on April 15, 2025, reporting $67,500 in lobbying income.
Lobbying for Denali Therapeutics · Biopharmaceutical Company
Filing · LD-2 quarterly report
Q1 amendment
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 15, 2025
Income
$67,500
What the client paid this registrant for the period.
Client based in
California
Lobbying activity
1
Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development